When was Evommune founded?

Evommune was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is Evommune located?

Evommune is headquartered in Sacramento, United States.

How many employees does Evommune have?

As of Jun 30, 2026, the latest employee count at Evommune is 68.

Is Evommune a funded company?

Evommune is a funded company, having raised a total of $276M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Oct 22, 2020.

When was the latest funding round of Evommune?

Evommune's latest funding was a $***** Post IPO round on Feb 12, 2026, with participation from 0 investor. Its primary sector is Immunology. In United States, the Immunology sector has seen $3.06B in funding in 2026 to date.

What is the annual revenue of Evommune?

Annual revenue of Evommune is between $10M and $50M as on Dec 31, 2025

Where does Evommune rank among its competitors?

Evommune ranks 47th amongst 2837 active competitors, of which 964 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Evommune?

Evommune's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Evommune - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of therapeutic options for chronic inflammatory disorders. The pipeline drug candidates include v for rosacea, and atopic dermatitis, RORγt for psoriasis, MRGPRX2 for pruritus, and PKCϴ for atopic dermatitis. The company uses a tissue-based screening platform that helps in the drug development of inflammatory diseases.

Website: evommune.com
Email ID: *****@evommune.com

Key Metrics

Founded Year

2020

Location

Sacramento, United States

Stage

Public

Total Funding

$276M in 6 rounds

Latest Funding Round

Post IPO, Feb 12, 2026, $*****

Investors

RA Capital Management & 19 more

Ranked

47^th among 2837 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2025

Employee Count

68 as on Jun 30, 2026

Similar Companies

Denali Therapeutics & 540 more

Exit Details

Public

View Evommune's full profile

Evommune is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
EVOMMUNE, INC. CIN: 2044725 , United States, Active		$10M - $50M (As on Dec 31, 2025)	-	-

Evommune got listed on Nov 06, 2025.

Click here to take a look at Evommune's IPO in detail

Evommune has raised a total funding of $276M over 6 rounds. Its first funding round was on Oct 22, 2020. Evommune has 20 institutional investors.

Here is the list of recent funding rounds of Evommune:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 12, 2026	2206641	Post IPO	1114679	3476687	3797613	3237196
Oct 30, 2024	6507629	Series C	9277711	5351094	1286823	RTW Investments & 13 more
Jun 28, 2023	2253891	Series B	2365325	6882606	Verition Fund Management	1834319

Access funding benchmarks and valuations. Sign up today!

View details of Evommune's funding rounds and investors

Evommune's employee count trend

Evommune has 68 employees as of Jun 26. Here is Evommune's employee count trend over the years:

Uncover Evommune's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Evommune include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Evommune, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	LEO Pharma 1908, Copenhagen (Denmark), Late Stage	Developer of drugs for treating dermatology diseases	$560M	Nordic Capital	71/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
47th	Evommune 2020, Sacramento (United States), Public	Developer of therapeutic options for chronic inflammatory disorders	$276M	RTW Investments, Marshall Wace & 18 others	66/100